TOLREMO Therapeutics AG
2 known investors
TOLREMO therapeutics develops small molecule inhibitors targeting transcriptional resistance mechanisms in cancer, with a lead clinical candidate TT125-802 designed for solid tumors and hematological malignancies as both monotherapy and combination treatment.
Investors · 2
Competitors · 2
by search overlapBioworld7 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Terremotobio5 shared keywordsTerremoto Bio develops next-generation small-molecule therapies using medicinal chemistry, targeting previously "undruggable" disease areas. The company focuses on drug candidates designed for improved efficacy and patient outcomes.
Companies competing with TOLREMO Therapeutics AG for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does TOLREMO Therapeutics AG do?
- TOLREMO therapeutics develops small molecule inhibitors targeting transcriptional resistance mechanisms in cancer, with a lead clinical candidate TT125-802 designed for solid tumors and hematological malignancies as both monotherapy and combination treatment.
- Who are TOLREMO Therapeutics AG's investors?
- TOLREMO Therapeutics AG's investors include BioMedPartners, redalpine.